Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Ramadan
Khaled M A
KM
Department of Haematology, Belfast City Hospital, Belfast, UK.
McKenna
Kevin E
KE
Morris
Treen C M
TC
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D017291:Clarithromycin / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007093:Imidazoles / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy; D000077268:Pamidronate; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use; D000077211:Zoledronic Acid
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D007166:Immunosuppressive Agents; D011500:Protein Synthesis Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077211:Zoledronic Acid; D003907:Dexamethasone; D017291:Clarithromycin; D000077268:Pamidronate; D008558:Melphalan; D015255:Idarubicin